JavaScript is required to use content on this page. Please enable JavaScript in your browser.
The Prescription Drug Affordability Board is an independent unit of state government tasked with protecting Marylanders and the Maryland health care system from the high costs of prescription drug products.
UPCOMING MEETING: Prescription Drug Affordability Board Meeting (Special Meeting), April 13, 2026 at 9:00 AM. Meeting information can be found here.
Written Comment Request: Staff has posted a revised versions of the Farxiga: Calculations and Analyses Underpinning Potential UPL Value (formerly Farxiga UPL Amount and Methodology Document) and Jardiance: Calculations and Analyses Underpinning Potential UPL Value (formerly Jardiance UPL Amount and Methodology Document). More information can be found here. Written public comments are requested. Comments may be submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Monday, April 6, 2026 to [email protected]
Data Request: The Maryland Prescription Drug Affordability Board may require covered entities and 340B manufacturers to report information as necessary to complete a study on the implementation, impact, and finances of the 340B program in Maryland, as outlined in 2024 Md. Laws, Chap. 962 (HB 1056). Please see the Data request webpage for more information. Information should be submitted by April 10, 2026 to [email protected].
We're available on the following channels.
